Specialized ERG products RetMap designs FDA-cleared, patented electrodes for electroretinography testing, positioning them as a specialized, high-value medical device supplier for clinics and hospitals performing retinal health assessments.

Growing seed financing The company secured a $1M seed round in a oversubscribed round, indicating investor confidence and potential for accelerated product development, regulatory milestones, and expanded sales reach.

Clinical relevance ERG testing is pivotal for diagnosing inherited retinal diseases and monitoring before structural damage appears, especially with emerging gene therapies, creating a broad and increasing demand pool for reliable, comfortable electrodes.

Small, focused team With a lean workforce (2-10 employees) and FDA-audited manufacturing, RetMap may be agile in partnering for contract manufacturing, clinical trials, and fast-cycle customer support for early adopters.

Growth potential channels Target clinics, ophthalmology groups, universities, and gene-therapy sponsors that require validated ERG solutions; leverage clinical publications and peer-reviewed data to drive adoption and premium pricing.